Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

Sperl J., Horvath G., Halota W., Arenas Ruiz-Tapiador J., Streinu-Cercel A., Jancoriene L., ...More

JOURNAL OF HEPATOLOGY, vol.65, no.6, pp.1112-1119, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 6
  • Publication Date: 2016
  • Doi Number: 10.1016/j.jhep.2016.07.050
  • Journal Name: JOURNAL OF HEPATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1112-1119
  • Hacettepe University Affiliated: Yes

Abstract

Background & Aims: Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) in patients with HCV infection.